{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"26"},{"groupId":"BG004","value":"59"}],"units":"Participants"}],"groups":[{"description":"Lenalidomide dose level 25 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m\\^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.","id":"BG000","title":"25 Mg Lenalidomide"},{"description":"Lenalidomide dose level 50 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m\\^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.","id":"BG001","title":"50 mg Lenalidomide"},{"description":"Lenalidomide dose level 75 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m\\^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.","id":"BG002","title":"75 mg Lenalidomide"},{"description":"Lenalidomide dose level 100 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m\\^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.","id":"BG003","title":"100 mg Lenalidomide"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"50","upperLimit":"63","value":"59"},{"groupId":"BG001","lowerLimit":"53","upperLimit":"70","value":"66"},{"groupId":"BG002","lowerLimit":"34","upperLimit":"72","value":"55"},{"groupId":"BG003","lowerLimit":"52","upperLimit":"71","value":"60"},{"groupId":"BG004","lowerLimit":"34","upperLimit":"72","value":"59.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"31"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"28"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"26"},{"groupId":"BG004","value":"59"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"Two participants were not eligible for study, and another two were eligible but did not receive required stem cell transplant therefore all appear in participation flow but two ineligible are not in baseline analysis population demographics."}